Skip to main content
NASDAQ:GWPH

GW Pharmaceuticals Competitors

$218.96
0.00 (0.00 %)
(As of 05/5/2021)
Add
Compare
Today's Range
$218.96
$218.96
50-Day Range
$216.90
$219.28
52-Week Range
$87.07
$219.57
VolumeN/A
Average Volume899,771 shs
Market Capitalization$6.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15

Competitors

GW Pharmaceuticals (NASDAQ:GWPH) Vs. RPRX, GMAB, CVAC, HZNP, CTLT, and ELAN

Should you be buying GWPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to GW Pharmaceuticals, including Royalty Pharma (RPRX), Genmab A/S (GMAB), CureVac (CVAC), Horizon Therapeutics Public (HZNP), Catalent (CTLT), and Elanco Animal Health (ELAN).

Royalty Pharma (NASDAQ:RPRX) and GW Pharmaceuticals (NASDAQ:GWPH) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Royalty Pharma and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
GW Pharmaceuticals-11.05%-7.46%-6.13%

Insider and Institutional Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Royalty Pharma and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
GW Pharmaceuticals$311.33 million22.05$-9,020,000.00($0.24)-912.33

Royalty Pharma has higher earnings, but lower revenue than GW Pharmaceuticals.

Analyst Ratings

This is a summary of recent recommendations and price targets for Royalty Pharma and GW Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
GW Pharmaceuticals010402.29

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 25.00%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.79%. Given Royalty Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Royalty Pharma is more favorable than GW Pharmaceuticals.

Summary

Royalty Pharma beats GW Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Genmab A/S and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Insider & Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Genmab A/S and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million31.12$324.68 million$0.5174.86
GW Pharmaceuticals$311.33 million22.05$-9,020,000.00($0.24)-912.33

Genmab A/S has higher revenue and earnings than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Genmab A/S and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24902.47
GW Pharmaceuticals010402.29

Genmab A/S presently has a consensus target price of $41.5714, suggesting a potential upside of 8.88%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.79%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than GW Pharmaceuticals.

Summary

Genmab A/S beats GW Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares CureVac and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
GW Pharmaceuticals-11.05%-7.46%-6.13%

Insider & Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CureVac and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
GW Pharmaceuticals$311.33 million22.05$-9,020,000.00($0.24)-912.33

CureVac has higher earnings, but lower revenue than GW Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11302.40
GW Pharmaceuticals010402.29

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 49.88%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.79%. Given GW Pharmaceuticals' higher probable upside, analysts plainly believe GW Pharmaceuticals is more favorable than CureVac.

Summary

GW Pharmaceuticals beats CureVac on 5 of the 9 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Horizon Therapeutics Public and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Horizon Therapeutics Public and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion16.22$573.02 million$1.9448.35
GW Pharmaceuticals$311.33 million22.05$-9,020,000.00($0.24)-912.33

Horizon Therapeutics Public has higher revenue and earnings than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Horizon Therapeutics Public and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
GW Pharmaceuticals010402.29

Horizon Therapeutics Public presently has a consensus target price of $111.3636, suggesting a potential upside of 18.74%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.79%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than GW Pharmaceuticals.

Summary

Horizon Therapeutics Public beats GW Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares Catalent and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.62$173 million$1.8854.27
GW Pharmaceuticals$311.33 million22.05$-9,020,000.00($0.24)-912.33

Catalent has higher revenue and earnings than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Catalent and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
GW Pharmaceuticals010402.29

Catalent presently has a consensus target price of $125.1250, suggesting a potential upside of 22.65%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.79%. Given Catalent's stronger consensus rating and higher probable upside, analysts plainly believe Catalent is more favorable than GW Pharmaceuticals.

Insider & Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Catalent and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Risk and Volatility

Catalent has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Summary

Catalent beats GW Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares GW Pharmaceuticals and Elanco Animal Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million22.05$-9,020,000.00($0.24)-912.33
Elanco Animal Health$3.07 billion5.39$67.90 million$1.0633.03

Elanco Animal Health has higher revenue and earnings than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for GW Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Elanco Animal Health13902.62

GW Pharmaceuticals currently has a consensus price target of $204.0909, suggesting a potential downside of 6.79%. Elanco Animal Health has a consensus price target of $33.1364, suggesting a potential downside of 5.35%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than GW Pharmaceuticals.

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares GW Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Elanco Animal Health-8.45%3.43%2.04%

Volatility & Risk

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Summary

Elanco Animal Health beats GW Pharmaceuticals on 11 of the 14 factors compared between the two stocks.


GW Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.50flat$25.20 billionN/A0.00Earnings Announcement
Analyst Revision
Genmab A/S logo
GMAB
Genmab A/S
1.2$38.18flat$25.04 billion$804.57 million29.60Analyst Report
Gap Up
CureVac logo
CVAC
CureVac
0.7$116.38flat$21.75 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.79flat$21.08 billion$1.30 billion25.63Insider Selling
Catalent logo
CTLT
Catalent
1.7$102.02flat$17.38 billion$3.09 billion64.98Analyst Revision
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$35.01flat$16.56 billion$3.07 billion-61.42Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89flat$15.97 billion$219.75 million-17.36Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$153.99flat$14.58 billion$12.98 million-50.82Earnings Announcement
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34flat$14.13 billion$1.70 billion17.70
Grifols logo
GRFS
Grifols
1.3$18.69flat$12.85 billion$5.71 billion16.69Analyst Upgrade
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00flat$11.97 billion$2.32 billion59.50Earnings Announcement
Analyst Report
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.76flat$11.75 billion$16.89 billion-2.92
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.25flat$10.48 billion$8.60 billion-5.37
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.80flat$10.06 billion$2.16 billion55.77Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$38.40flat$9.89 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$198.29flat$8.88 billion$1.45 billion18.76
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.13flat$8.08 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.50flat$8.00 billion$3.34 million-20.19Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$73.05flat$7.60 billion$87.99 million-86.96
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.29flat$7.44 billion$103.71 million-25.12
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$135.63flat$7.29 billion$14.98 million-16.52Upcoming Earnings
Perrigo logo
PRGO
Perrigo
2.2$45.46flat$6.07 billion$4.84 billion-757.54Earnings Announcement
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$75.13flat$5.99 billion$380.83 million-9.61
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.88flat$5.48 billion$66.51 million17.32Insider Selling
Allakos logo
ALLK
Allakos
1.7$100.54flat$5.39 billionN/A-36.69Analyst Downgrade
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32flat$5.26 billion$1.12 billion77.75Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$77.00flat$5.04 billion$1.00 billion-11.67Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$33.85flat$4.79 billion$150,000.00-15.97Earnings Announcement
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.2$63.60flat$4.60 billion$4.31 million-2.20News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.27flat$4.57 billionN/A-5.73Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.6$61.45flat$4.30 billion$85.54 million0.00Insider Selling
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$53.06flat$4.27 billionN/A-7.15Analyst Report
Unusual Options Activity
News Coverage
Gap Up
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$72.75flat$4.25 billion$6.87 million-7.03
LEGN
Legend Biotech
1.3$30.90flat$4.11 billion$64.39 million0.00Analyst Report
High Trading Volume
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.75flat$3.98 billion$204.89 million-33.44
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89flat$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08flat$3.54 billion$1.17 billion-48.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$70.45flat$3.46 billionN/A-20.07
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.72flat$3.43 billion$117.91 million-11.30
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.23flat$3.40 billion$339.08 million-12.34Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.19flat$3.32 billion$114.62 million-7.33Analyst Report
Insider Selling
Arvinas logo
ARVN
Arvinas
1.7$67.24flat$3.29 billion$42.98 million-26.27
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$110.73flat$3.26 billionN/A-55.09
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29flat$3.23 billion$1.11 billion19.39
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.10flat$3.01 billion$60,000.00-11.52Analyst Upgrade
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$79.07flat$2.86 billion$26.52 million-6.97
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.29flat$2.80 billion$644.77 million-10.46Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.93flat$2.75 billion$80.43 million99.67
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.60flat$2.71 billion$421.03 million21.69Analyst Report
Insmed logo
INSM
Insmed
1.2$26.04flat$2.69 billion$136.47 million-10.02Analyst Report
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.